Imagine the high-stakes moment in an emergency room or ICU where a critically ill patient's life hangs in the balance during tracheal intubation—the insertion of a tube to help them breathe—and the anesthetic you choose could tip the scales toward stability or crisis. A groundbreaking large-scale randomized trial has just revealed that ketamine isn't the superior option we once believed it to be compared to etomidate, challenging long-held assumptions in critical care medicine.
In the world of anesthesiology, tracheal intubation is a crucial procedure for patients who can't breathe on their own, often in life-threatening situations like severe infections or shock. Etomidate has been the go-to drug for inducing anesthesia before this step because it's quick and effective, but it comes with a downside: it can suppress the adrenal glands, potentially leading to a shortage of corticosteroids that the body needs to fight stress and illness. This adrenal suppression has sparked worries about increased death risks, prompting some countries to restrict etomidate's use and pushing doctors toward alternatives that might destabilize blood pressure and heart function even more.
But here's where it gets controversial: despite these concerns, a major pragmatic clinical trial published in the New England Journal of Medicine on December 9, 2025, found that using ketamine instead of etomidate didn't improve survival rates or reduce heart-related complications during intubation for critically ill adults. Led by Jonathan Casey, MD, MSc, from Vanderbilt University Medical Center in Nashville, Tennessee, the study tracked 2,365 patients aged 18 and older (with a median age of 60) across six U.S. medical centers, including emergency departments and ICUs. These patients were randomly split evenly to receive either intravenous ketamine or etomidate for anesthesia induction before intubation. To keep things focused, the trial excluded pregnant individuals, those with primary trauma diagnoses, cases needing immediate intubation without time for randomization, or situations where one drug was clearly necessary or forbidden.
The results? By day 28, in-hospital death rates were nearly identical: 28.1% for the ketamine group and 29.1% for the etomidate group, with no statistically significant difference (P=0.65). This challenges the popular belief that ketamine, known for its ability to preserve blood pressure and heart rate (hemodynamic stability), would be a safer bet—especially since prior large observational studies hinted at lower mortality with ketamine, though smaller trials left the question open-ended.
And this is the part most people miss: not only did ketamine fail to boost survival, but it actually showed a trend toward more cardiovascular issues. The risk of cardiovascular collapse during intubation—defined as systolic blood pressure dropping below 65 mm Hg, needing new or higher doses of vasopressors (medications to support blood pressure), or experiencing cardiac arrest—happened in 22.1% of ketamine patients versus 17.0% of etomidate patients (a risk difference of 5.1 percentage points, 95% CI 1.9-8.3). Other safety measures, like hypotension, vasopressor use, and even ventricular tachycardia (a dangerous heart rhythm), were slightly higher with ketamine. These findings were also shared at the Critical Care Reviews meeting in Melbourne, Australia, adding weight to the evidence.
The trial's diverse patient group included 46.7% with sepsis or septic shock—a severe infection response that can lead to organ failure—and 22.0% already on vasopressors. Interestingly, the gaps in cardiovascular complications widened in these high-risk subgroups: for sepsis patients, collapse rates were 30.6% with ketamine versus 20.9% with etomidate; for those with severe illness (APACHE II score of 20 or higher, a scoring system that gauges critical condition severity), it was 31.4% versus 20.7%. Sensitivity analyses and subgroup breakdowns, including by sepsis status, mirrored the overall results, reinforcing the reliability.
This data clashes with some expert guidelines that specifically endorse ketamine for septic patients or those on vasopressors, as outlined in resources like the Surviving Sepsis Campaign. Yet, it aligns with two observational studies and one prior randomized trial that also spotted more heart issues with ketamine. For beginners, think of it this way: while etomidate might quietly harm the stress response system, ketamine's supposed stability benefits didn't pan out in this real-world setting, possibly because both drugs have trade-offs in fragile patients.
Of course, no study is perfect. The trial's open-label design (where patients and doctors knew which drug was used) and exclusion of trauma cases might limit how broadly we apply these results. Plus, as Casey and his team from the Pragmatic Critical Care Research Group pointed out, small outcome differences between these common drugs could still matter clinically—we can't rule them out entirely. And importantly, these insights don't extend to other anesthetics like propofol (which can drop blood pressure sharply), benzodiazepines, or barbiturates; each has its own profile.
So, what does this mean for frontline clinicians? It suggests sticking with etomidate might be as safe as switching to ketamine, despite the adrenal concerns—potentially easing restrictions and rethinking protocols. But here's a subtle counterpoint to stir debate: could the trial's U.S.-centric focus overlook how patient populations or drug dosing vary globally, leading to different outcomes elsewhere? Do you agree that guidelines should pivot based on this evidence, or is more research needed before ditching ketamine recommendations for septic cases? Share your thoughts in the comments—your insights as a healthcare pro or curious reader could spark the next big discussion!
